System Certification ISO 9001:2000
Exbio Antibodies CZ / SK eShop
by categories | a-z list | Application type: Flow Cytometry | Immunohistochemistry | Functional Studies

Hamster Monoclonal to CD79b (mouse)

HM79 (IgG2)

Technical Information Request    Inquiry for Bulk Prices

Product No. Form Quantity Stock Price Datasheet Shop
  11-584-C100 purified 0.1 mg yes choose region PDF datasheetHTML datasheet buy
  11-584-C500 purified 0.5 mg yes choose region PDF datasheetHTML datasheet buy
  1F-584-C100 FITC 0.1 mg yes choose region PDF datasheetHTML datasheet buy
  1P-584-C025 PE 0.025 mg yes choose region PDF datasheetHTML datasheet buy
  1P-584-C100 PE 0.1 mg yes choose region PDF datasheetHTML datasheet buy
- In stock! Ready for immediate despatch - Manufacture on order

Background

CD79b (Ig beta, B29) forms disulfide-linked heterodimer with CD79a (Ig alpha, MB1). They both are transmembrane proteins with extended cytoplasmic domains containing immunoreceptor tyrosine activation motives (ITAMs), and together with cell surface immunoglobulin they constitute B-cell antigen-specific receptor (BCR). CD79a and b are the first components of BCR that are expressed developmentally. They appear on pro-B cells in association with the endoplasmic reticulum chaperone calnexin. Subsequently, in pre-B cells, CD79 heterodimer is associated with lambda5-VpreB surrogate immunoglobulin and later with antigen-specific surface immunoglobulins. CD79a/b complex interacts with Src-family tyrosine kinase Lyn, which phosphorylates its cytoplasmic ITAM motives to form docking sites for downstream signaling.

Specificity

The Armenian hamster monoclonal antibody HM79 recognizes an extracellular epitope of mouse CD79b (CD79 beta, Ig beta), a component of B cell receptor (BCR) complex.

Regulatory Status

Immunogen

Purified CD79a/b (alpha/beta) dimers from WEHI231 cells

Species Reactivity:

  • Mouse

Negative Species:

  • Human

Applications:

  • Flow Cytometry
    Recommended dilution:1 μg/ml
  • Immunoprecipitation
  • Western Blotting
  • Immunocytochemistry
Usage note:
Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.

General references

  • *Gong S, Nussenzweig MC: Regulation of an early developmental checkpoint in the B cell pathway by Ig beta. Science. 1996 Apr 19;272(5260):411-4. [Abstract]
  • *Teh YM, Neuberger MS: The immunoglobulin (Ig)alpha and Igbeta cytoplasmic domains are independently sufficient to signal B cell maturation and activation in transgenic mice. J Exp Med. 1997 May 19;185(10):1753-8. [Abstract] [Full Text]
  • *Nagata K, Nakamura T, Kitamura F, Kuramochi S, Taki S, Campbell KS, Karasuyama H: The Ig alpha/Igbeta heterodimer on mu-negative proB cells is competent for transducing signals to induce early B cell differentiation. Immunity. 1997 Oct;7(4):559-70. [Abstract]
  • *Kouro T, Nagata K, Takaki S, Nisitani S, Hirano M, Wahl MI, Witte ON, Karasuyama H, Takatsu K: Bruton's tyrosine kinase is required for signaling the CD79b-mediated pro-B to pre-B cell transition. Int Immunol. 2001 Apr;13(4):485-93. [Abstract]
  • *Fuentes-PananŠ EM, Bannish G, Shah N, Monroe J.G.: Basal Igalpha/Igbeta signals trigger the coordinated initiation of pre-B cell antigen receptor-dependent processes. J Immunol. 2004 Jul 15;173(2):1000-11. [Abstract] [Full Text]
  • *Fuentes-PananŠ EM, Bannish G, van der Voort D, King LB, Monroe J.G.: Ig alpha/Ig beta complexes generate signals for B cell development independent of selective plasma membrane compartmentalization. J Immunol. 2005 Feb 1;174(3):1245-52. [Abstract] [Full Text]
  • Product Specific References

  • *Koyama M, Ishihara K, Karasuyama H, Cordell JL, Iwamoto A, Nakamura T: CD79 alpha/CD79 beta heterodimers are expressed on pro-B cell surfaces without associated mu heavy chain. Int Immunol. 1997 Nov;9(11):1767-72. [Abstract] [Full Text]
  • *Maki K, Nagata K, Kitamura F, Takemori T, Karasuyama H: Immunoglobulin beta signaling regulates locus accessibility for ordered immunoglobulin gene rearrangements. J Exp Med. 2000 Apr 17;191(8):1333-40. [Abstract] [Full Text]
  • *Li Y, Chen F, Putt M, Koo YK, Madaio M, Cambier JC, Cohen PL, Eisenberg RA: B cell depletion with anti-CD79 mAbs ameliorates autoimmune disease in MRL/lpr mice. J Immunol. 2008 Sep 1;181(5):2961-72. [Abstract]
  • *Aiba Y, Kameyama M, Yamazaki T, Tedder TF, Kurosaki T: Regulation of B-cell development by BCAP and CD19 through their binding to phosphoinositide 3-kinase. Blood. 2008 Feb 1;111(3):1497-503. [Abstract] [Full Text]
  • *Kouro T, Nagata K, Takaki S, Nisitani S, Hirano M, Wahl MI, Witte ON, Karasuyama H, Takatsu K: Bruton's tyrosine kinase is required for signaling the CD79b-mediated pro-B to pre-B cell transition. Int Immunol. 2001 Apr;13(4):485-93. [Abstract] [Full Text]
  • For research use only. Not for drug, diagnostic or other use.

    Example Data

    HM79 PE


    Fig. 1. Surface staining of CD79b in murine splenocytes with anti-CD79b (HM79) PE.

    Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIOīs term and conditions which are available at www.exbio.cz.
    © 2003 EXBIO. All rights reserved.
    terms and conditions | privacy policy